Ticagrelor: a review of its cost effectiveness in the management of acute coronary syndromes


    loading  Checking for direct PDF access through Ovid

Abstract

Ticagrelor (Brilique™ [EU]; Brilinta® [USA]), an oral antiplatelet agent, is indicated in combination with aspirin for the prevention of atherothrombotic events in adults with acute coronary syndromes (ACS). In a key 12-month trial in patients with ACS, ticagrelor plus aspirin prevented ischaemic events more effectively than clopidogrel plus aspirin, without increasing the risk of most major bleeding events. Despite some inherent limitations, available pharmacoeconomic data from a healthcare payer perspective in several countries support the use of ticagrelor as a cost-effective treatment to prevent atherothrombotic events in patients with ACS relative to generic and brand-name clopidogrel.

    loading  Loading Related Articles